Theralizumab Biosimilar - Research Grade

Product Sizes

1 mg

ICH5023-1MG

5 mg

ICH5023-5MG

10 mg

ICH5023-10MG

20 mg

ICH5023-20MG

50 mg

ICH5023-50MG

100 mg

ICH5023-100MG

200 mg

ICH5023-200MG

500 mg

ICH5023-500MG

1 g

ICH5023-1G

About this Product

SKU:: ICH5023
Additional Names:: TGN1412, CD28-SuperMAB, TAB08
Application:: Cell-based/Functional Assay
CE/IVD:: RUO
Clonality:: Recombinant Monoclonal
Concentration:: 5 mg/ml
Extra Details:: Theralizumab GN1412 is a humanised monoclonal antibody that not only binds to, but is a strong agonist for, the CD28 receptor of the immune system's T cells. CD28 is the co-receptor for the T cell receptor; It binds to receptors on the interacting partner in the reaction through one of its ligands (B7 family). It was withdrawn from development after inducing severe inflammatory reactions as well as chronic organ failure in the first-in-human study by PAREXEL in London in March 2006.
Formulation:: Sterile, preservative-free, solution in PBS. BSA and Azide free.
Immunogen:: CD28
Isotype:: IgG4
Purity:: >95%
Purification:: Protein A/G Purified
Reactivities:: Human
Shipping Conditions:: Blue Ice
Specificity:: Detects human CD28. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Theralizumab.
Storage Conditions:: -70[o]C Avoid freeze/thaw cycles.
Supplier:: ichorbio
Type:: Antibody: Biosimilar Antibody
Shipping Costs:: Free shipping to UK Customers

Basket